Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Anti-tau VHH therapy against PHF6: a safe approach to slowing the phenotype of tau pathology.

Alzheimer's research & therapy - 7 Oct 2025

Caillierez Raphaelle, Leboullenger Clémence, Leclercq Sarah, Besegher Mélanie, Bégard Séverine, Auger Florent, Maurage Claude-Alain, Accart Bertrand, Mortelecque Justine, Dupré Elian, Danis Clément, Landrieu Isabelle, Buée Luc, Colin Morvane

Abstract excerpt

BACKGROUND: Tauopathies share common features, including tau aggregation, which plays a central role in neurodegeneration. However, these disorders are highly heterogeneous, particularly in the spread of pathological tau species between cells. In Alzheimer's disease, intracellular tau aggregation is followed by a propagation between cells leading to a hierarchical pathway of neurodegeneration, whereas in other...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer Disease
Share to Brain

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Models, Animal

Share to Mice, Inbred C57BL

Share to Mice, Transgenic

Share to Single-Domain Antibodies

Share to tau Proteins

Share to Tauopathies

Source

Open in PubMed Open full text

Identifiers

PMID: 41057930
DOI: 10.1186/s13195-025-01823-6
PMCID: PMC12505654

Genes

PHF6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anti-tau VHH therapy against PHF6: a safe approach to slowing the phenotype of tau pathology.PMID 41057930Read ↗

Anti-Tau VHH Therapy Against PHF6: A Safe Approach to Slowing the Phenotype of Tau PathologySemantic proximity Read ↗

Inhibition of Tau seeding by targeting Tau nucleation core within neurons with a single domain antibody fragmentSemantic proximity Read ↗

A selection and optimization strategy for single-domain antibodies targeting the PHF6 linear peptide within the tau intrinsically disordered proteinSemantic proximity Read ↗

Anti-tau intrabodies: From anti-tau immunoglobulins to the development of functional scFv intrabodiesSemantic proximity Read ↗

Strategy of selection and optimization of single domain antibodies targeting the PHF6 linear peptide within the Tau intrinsically disordered proteinSemantic proximity Read ↗

Inhibition of tau neuronal internalization using anti-tau single domain antibodiesSemantic proximity Read ↗

Tau pSer396 and pSer404 Define Distinct Epitope Regions Linked to Different Antibody FunctionsSemantic proximity Read ↗

Single Domain Antibody Fragments as New Tools for the Detection of Neuronal Tau Protein in Cells and in Mice StudiesSemantic proximity Read ↗

Early or late-stage anti-N-terminal Huntingtin intrabody gene therapy reduces pathological features in B6.HDR6/1 mice.Semantic proximity Read ↗

Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer’s diseaseSemantic proximity Read ↗

Anti-tau scFvs Targeted to the Cytoplasm or Secretory Pathway Variably Modify Pathology and Neurodegenerative PhenotypesSemantic proximity Read ↗

Targeting intracellular tau with a gene-encoded single-chain antibody promotes neuronal homeostasis and ameliorates tau pathologySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.